Hybrid (Bisarylmethoxy)butylpiperazine Analogs as Neurotransmitter Transporter Inhibitors with Activity at Dopamine Receptor Sites as Potential Cocaine Antagonists

키워드

참고문헌 (62)

1. Johanson, C. -E, "The Pharmacology of Cocaine Related to its Abuse", Pharmacol. Rev, 41, pp.3~52 (1989)
2. Clouet, D., "Mechanisms of Cocaine Abuse and Toxicity", NIDA Res. Monogr, 88, pp.78~91 (1988)
3. Musto, D. F, "Opium, Cocaine, and Marijuana in American History", Sci. Am., 265, pp.40~47 (1991)
4. Barbosa de Carvalho H, "Crack Cocaine Use and its Relationship with Violence and Hiv", Clinics (Sao Paulo), 64, pp.857~866 (2009)
5. Erickson P.G., "Crack and prostitution: gender, myths, and experiences", J Drug Issues, 30, pp.767~788 (2000)
6. Negrusz A, "Detection of Cocaine on Various Denominations of United States Currency", J. Forensic Sci, 43, pp.626~629 (1998)
7. Strano- Rossi, S., "Segmental hair analysis for cocaine and heroin abuse determination", Forensic Sci. Int, 70, pp.211~216 (1995)
8. Carroll. F. I., "Cocaine Receptor: Biochemical Characterization and Structure-Activity Relationships of Cocaine Analogs at the Dopamine Transporter", J. Med. Chem., 35, pp.969~981 (1992)
9. Carroll, F. I., "Pharmacotherapies for Treatment of Cocaine Abuse: Preclinical Aspects", J. Med. Chem., 42, pp.1~16 (1999)
10. Gorelick D.A., "Agents in development for the management of cocaine abuse", Drugs, 14, pp.1547~1573 (2004)
11. Ritz. M. C., "Cocaine Receptors on Dopamine Transporters are Related to Self-Administration of Cocaine", Science, 237, pp.1219~1222 (1987)
12. Kuhar. M. J., "The Dopamine Hypothesis of the Reinforcing Properties of Cocaine", Trends Neurosci, 14, pp.299~302 (1991)
13. Giros. B., "Hyperlocomotion and Indifference to Cocaine and Amphetamine in Mice Lacking the Dopamine Transporter", Nature, 379, pp.606~612 (1996)
14. Thomsen M., "Dramatically Decreased Cocaine Self-Administration in Dopamine But Not Serotonin Transporter Knock-Out Mice", J. Neurosci, 29, pp.1087~1092 (2009)
15. cocaine binding in central nervous system of mouse, "Life Sci", 1980, 1055~1062
16. Cocaine in Mouse Striatum is Serotonin Related, "Brain Res", 1985, 145~148
17. Mello, N. K., "Preclinical Evaluation of Pharmacotherapies for Treatment of Cocaine and Opioid Abuse Using Drug Self-Administration Procedures", Neuropsychopharmacology, 14, pp.375~424 (1996)
18. Witkin, J. M, "Pharmacotherapy of Cocaine Abuse: Preclinical Development", Neurosci. Biobehav. Rev., 18, pp.121~142 (1994)
19. Witkin, J. M., "Interaction of haloperidol and SCH 23390 with cocaine and dopamine receptor subtype-selective agonists on schedule-controlled behavior of squirrel monkeys", Psychopharmacology, 104, pp.425~431 (1991)
20. Spealman, R. D, "Antagonism of behavioral effects of cocaine by selective dopamine receptor blockers", Psychopharmacology, 101, pp.142~145 (1990)
21. Corrigal, W. A., "Cocaine self-administration is increased by both D1 and D2 dopamine antagonists", Pharmacol. Biochem. Behav, 39, pp.799~802 (1991)
22. Britton, D. R., "Evidence for involvement of both D1 and D2 receptors in maintaining cocaine self-administration", Pharmacol. Biochem. Behav, 39, pp.911~915 (1991)
23. Shafer, R. A., "The D3 dopamine receptor in cellular and organismal function", Psychopharmacology, 135, pp.1~16 (1998)
24. Pilla, M., "Selective Inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist", Nature, 400, pp.371~375 (1999)
25. , on the Reinforcing and Discriminative Stimulus Effects of Cocaine in Rhesus Monkeys, "J. Pharmacol. Exp. Ther.", 2007, 573~582
26. DA-uptake-inhibition to transporter- binding-inhibition ratios for the in vitro evaluation of putative cocaine antagonists, "Life Sci", 1993, PL267~PL272
27. alkane Dopamine Uptake Inhibitors, "J. Med. Chem", 1999, 882~895
28. Nader, M. A., "The reinforcing and discriminative stimulus effects of the novel cocaine analog 2betapropanoyl- 3beta-(4-tolyl)-tropane in rhesus monkeys", J. Pharmacol. Exp. Ther, 280, pp.541~550 (1997)
29. Simoni, D., "Methoxylation of cocaine reduces binding affinity and produces compounds of differential binding and dopamine uptake inhibitory activity: discovery of a weak cocaine “antagonist”", J. Med. Chem, 36, pp.3975~3977 (1993)
30. Zhang. Y., "The Identification of GBR 12909 as a Potential Therapeutic Agent for Cocaine Abuse", Med. Chem. Res., 8, pp.66~76 (1998)
31. -4-(3-phenylpropyl)piperazine (GBR 12935 and GBR 12909), "J. Med. Chem.", 1996, 4704~4716
32. -4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as High Affinity Dopamine Reuptake Inhibitors, "J. Med. Chem", 1997, 705~716
33. Madras. B. K., "0-526, a piperidine analog of GBR 12909, retains high affinity for the dopamine transporter in monkey caudate-putamen", Eur. J. Pharmacol, 267, pp.167~173 (1994)
34. -1-benzylpiperidine for the Dopamine Transporter: Effect of Different Aromatic Substitutions on Their Affinity and Selectivity, "J. Med. Chem", 1997, 35~43
35. Baumann. M. H., "GBR 12909 Attenuates Cocaine -Induced Activation of Mesolimbic Dopamine Neurons in the Rat", J. Pharmacol. Exp. Ther, 271, pp.1216~1222 (1994)
36. Rothman. R. B., "GBR 12909 Antagonizes the Ability of Cocaine to Elevate Extracellular Levels of Dopamine", Pharmacol. Biochem. Behav, 40, pp.387~396 (1991)
37. Van der Zee. P., "Aryl 1.4-Dialk(en)yl Piperazines as Selective and Very Potent Inhibitors of Dopamine Uptake", Eur. J. Med. Chem, 15, pp.363~370 (1980)
38. Tella. S. R., "Differential Reinforcing Effects of Cocaine and GBR-12909: Biochemical Evidence for Divergent Neuroadaptive Changes in the Mesolimbic Doparminergic System", J. Neurosci, 16, pp.7416~7427 (1996)
39. -4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as Potential Extended Cocaine-Abuse Therapeutic Agents, "J. Med. Chem", 1999, 5029~5042
40. Bergman, J., "Effects of Cocaine and Related Drugs in Nonhuman Primates. III. Self-Administration by Squirrel Monkeys", J. Pharmacol. Exp. Ther, 251, pp.150~155 (1989)
41. Howell, L. L., "Characterization of the Effects of Cocaine and GBR 12909, a Dopamine Uptake inhibitor, on Behavior in the Squirrel Monkey", J. Pharmacol. Exp. Ther., 258, pp.178~185 (1991)
42. Katz, J. L., "Relationships among dopamine transporter affinities and cocaine-like discriminative- stimulus effects", Psychopharmacology, 148, pp.90~98 (2000)
43. Howell, L. L, "Pharmacological Interactions between serotonin and dopamine on behavior in the squirrel monkey", Psychopharmacology, 131, pp.40~48 (1997)
44. Deutsch. H., "Can stimulant binding and dopamine transport be differentiated? Studies with GBR 12783 derivatives", Life Sci, 55, pp.PL115~PL121 (1994)
45. Hanson, R. N., "Synthesis and Evaluation of Novel-N-[2- (Bis-Aryl-Methoxy)Ethyl-N’-Aralkyl-Alkanediamines as Potent and Selective Dopamine Reuptake Inhibitors: Seco Analogs of GBR 12935 and GBR 12909", Bioorg. Med. Chem. Lett., 7, pp.2559~2564 (1997)
46. -4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as Dopamine Transporter Inhibitors, "J. Med. Chem", 1999, 3647~3656
47. Dutta. A. K., "Positional importance of the nitrogen atom in novel piperidine analogs of GBR 12909: Affinity and selectivity for the dopamine transporter", Med. Chem. Res, 3, pp.209~222 (1993)
48. Ahmad, Y. E., "New N-(benzhydroxyalkyl)-4-(carboxy", carbamoylmethyl) piperidine derivatives with Antidepressant Activity, 1997, pp.32, 205~218
49. Taverne, T., "Novel Ben zothiazolin-2-one and Benzoxan-3-one Arylpiperazine Derivatives with Mixed 5HT1A", D2 Affinity as Potential Atypical Antipsychotics, 1998, pp.41, 2010~2018
50. Neves G., "Searching for multitarget antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5- HT1A receptors", Bioorg. Med. Chem, 18, pp.1925~1935 (2010)
51. Caliendo, G, "Synthesis of New 1,2,3-Benzotriazin-4-one-arylpiperazine Derivatives as 5-HT1A Serotonin Receptor Ligands", Bioorg. Med. Chem, 8, pp.533~538 (2000)
52. Chu W., "Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands", Bioorg Med Chem., 13, pp.77~87 (2005)
53. Choi S-W, "Novel (bisarylmethoxy)butylpiperidine analogues as neurotransmitter transporter inhibitors with activity at dopamine receptor sites", Bioorg Med Chem, 10, pp.4091~4102 (2002)
54. Aspinal. S. R., "A synthesis of Monoketopiperazine", J. Am. Chem. Soc, 62, pp.1202~1204 (1940)
55. Roderick, W. R., "Derivatives of piperazine. XXXV. Synthesis of 2-Phenylpiperazine and Some Derivatives", J. Am. Chem. Soc., 9, pp.181~185 (1966)
56. Eshleman, A. J., "Characteristics of Drug Interactions with Recombinant Biogenic Amine Transporters Expressed in the Same Cell Type", J. Pharmacol. Exp. Ther, 289, pp.877~885 (1999)
57. "In vitro pharmacological assays for receptors by NIDA", MDD (NIDA contract NO1DA-7-8072, Contract title: “Receptor Activity Testing for Medication Discovery”
58. Chio, C. L., "Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors", Mol. Pharmacol, 45, pp.51~60 (1994)
59. Glennon, R. A., "N-(Phthalimidoalkyl) derivatives of Serotonergic Agents: A Common Interaction at 5-HT1A Serotonin Binding Sites?", J. Med. Chem, 32, pp.1921~1926 (1989)
60. Morreale, A., "Arylpiperazines with Serotonin-3 Antagonist Activity: A Comparative Molecular Field Analysis", J. Med. Chem., 41, pp.2029~2039 (1998)
61. Dubinsky, B., "Bromperidol, a New Butyrophenone Neuroleptic: A Review", Psychopharmacology, 78, pp.1~7 (1982)
62. Manzanedo, C., "The effects of dopamine D2 and D3 antagonists on spontaneous motor activity and morphine-induced hyperactivity in male mice", Psychopharmacology, 143, pp.82~88 (1999)

관련 논문AI추천